4.7 Review

Class 3 semaphorins: physiological vascular normalizing agents for anti-cancer therapy

Journal

JOURNAL OF INTERNAL MEDICINE
Volume 273, Issue 2, Pages 138-155

Publisher

WILEY
DOI: 10.1111/joim.12017

Keywords

angiogenesis; cancer; endothelial function; metastasis; oncology; vascular biology

Funding

  1. Associazione Italiana per la Ricerca sul Cancro (AIRC) [11600, 9211, 10133]
  2. AIRC [9970]
  3. Associazione Augusto per la Vita
  4. Fondazione Piemontese per la Ricerca sul Cancro [5 x 1000 2008]
  5. University of Torino
  6. Telethon, Italy
  7. Fondazione Italiana per la Ricerca sul Cancro (FIRC)

Ask authors/readers for more resources

Serini G, Bussolino F, Maione F, Giraudo E (Institute for Cancer Research at Candiolo (IRCC), University of Torino, Turin, Italy). Class 3 semaphorins: physiological vascular normalizing agents for anti-cancer therapy (Review). J Intern Med 2013; 273: 138-155. Findings from preclinical and clinical studies show that vascular normalization represents a novel strategy to enhance the efficacy of and overcome the acquired resistance to anti-angiogenic therapies in cancer. Several mechanisms of tumour vessel normalization have been revealed. Amongst them, secreted class 3 semaphorins (Sema3), which regulate axon guidance and angiogenesis, have been recently identified as novel vascular normalizing agents that inhibit metastatic dissemination by restoring vascular function. Here, we discuss the different biological functions and mechanisms of action of Sema3 in the context of tumour vascular normalization, and their impact on the different cellular components of the tumour microenvironment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available